The concordance between tissue and circulating tumor DNA testing is well-established. However, clinicians may be confronted with discrepant results, especially when performing tissue and liquid testing in parallel, and interpretation may not be so straightforward.
In this Vessel Briefing, we will address some basic concepts and provide case studies to raise awareness about this factor that affects treatment decisions.
Join us on January 12th, 2023. 5PM CET/6PM EET
Please join the conversation and post your comments, thoughts and questions below leading up the the briefing.
See you inside. Members have full access to this document
Your North Star in the Transformation of Precision Oncology
Consider applying to access:
Already have an account?
- Comprehensive Educational Programs
- Ongoing Professional Development
- Exclusive Access to the Vessel Community
You’ve successfully subscribed to Vessel
Welcome back! You’ve successfully signed in.
Great! You’ve successfully signed up.
Success! Your email is updated.
Your link has expired
Success! Check your email for magic link to sign-in.